INmune Bio (INMB)
(Delayed Data from NSDQ)
$8.35 USD
-0.23 (-2.68%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $8.37 +0.02 (0.24%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INMB 8.35 -0.23(-2.68%)
Will INMB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INMB
Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?
INMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Analysts Initiate Coverage: 5 Stocks for Higher Returns
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
Other News for INMB
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro? on Proteins that Regulation Synapses in Alzheimer?s Patients
INmune Bio announces new Phase 1 study data on XPro
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
Inmune Bio’s Clinical Advancements Secure Buy Rating from Analyst Jason McCarthy
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune? in the Journal for ImmunoTherapy of Cancer